This page provides an index of biotechnology and pharmaceutical companies actively developing treatments for Parkinson's disease (PD).
The Parkinson's disease drug development landscape includes companies targeting various pathological mechanisms:
- Alpha-synuclein: Targeting aggregation and spreading
- LRRK2: Genetic risk factor inhibition
- GBA: Glucocerebrosidase modulation
- Mitochondrial function: Protecting dopaminergic neurons
- Neuroinflammation: Microglial modulation
- Dopamine replacement: Symptomatic treatments
| Company |
Key Drugs |
Phase |
| Biogen Inc. |
BIIB122 (Phase 2b) |
Phase 2b |
| Eli Lilly |
- |
Various |
| AbbVie |
- |
Preclinical |
| Roche |
- |
Various |
| Eisai |
- |
Various |
| Company |
Key Drugs |
Phase |
| Astellas Pharma |
ND0612 (infusion), ASP001, ASP4583 |
Phase 1-3 |
| Takeda Pharmaceutical |
T-052, T-345 (LRRK2 inhibitor) |
Phase 1 |
| Kyowa Kirin |
Nourianz (istradefylline), Potelacizumab |
Marketed/Phase 1 |
| Daiichi Sankyo |
DS-7891, DS-7785 (LRRK2 inhibitor) |
Phase 1 |
| Eisai |
E2027 (PDE9 inhibitor) |
Phase 2 |
Astellas has a significant Parkinson's disease pipeline including ND0612, a continuous levodopa/carbidopa infusion system in Phase 3, and multiple early-stage programs targeting alpha-synuclein and LRRK2.
Takeda's neuroscience programs include T-052 (alpha-synuclein aggregation inhibitor) and T-345 (LRRK2 inhibitor) in Phase 1 development for PD. [^4]
Kyowa Kirin markets Nourianz (istradefylline), an adenosine A2A antagonist approved in Japan for Parkinson's disease "off" periods, and is developing Potelacizumab, an anti-alpha-synuclein antibody. [^5]
Daiichi Sankyo has Phase 1 programs including DS-7891 and DS-7785 (LRRK2 inhibitor) for Parkinson's disease. [^6]
| Company |
Key Drug |
Mechanism |
Phase |
| Denali Therapeutics Inc. |
DNL151 (BIIB122) |
LRRK2 inhibitor |
Phase 2b |
| Prothena Corporation |
Prasinezumab |
Anti-α-syn mAb |
Phase 2 |
| Annovis Bio, Inc. |
Bunodimod |
Sigma-1 agonist |
Phase 2/3 |
| AbbVie |
- |
- |
Phase 2 |
| Company |
Focus Area |
| Vaxxinity |
Therapeutic vaccines |
| INmune Bio |
Neuroinflammation |
| Vanqua Bio |
LRRK2 inhibitors |
| Gain Therapeutics |
Protein stabilization |
| Pinteon Therapeutics |
Tau immunotherapy |
| Prevail Therapeutics |
Gene therapy |
| Passage Bio |
Gene therapy |
| Neuraly |
Alpha-synuclein immunotherapy |
India is a major global hub for generic pharmaceutical manufacturing, with several companies producing affordable Parkinson's disease medications for markets worldwide.
| Company |
PD Products |
Market Reach |
| Sun Pharmaceutical Industries |
Levodopa/Carbidopa, Ropinirole, Pramipexole, Rasagiline |
Global (100+ countries) |
| Dr. Reddy's Laboratories |
Levodopa, Carbidopa, Ropinirole, Pramipexole, Entacapone |
Global (US, Europe, India) |
| Lupin Pharmaceuticals |
Levodopa, Ropinirole, Pramipexole, Rotigotine, Selegiline |
Global (US, Japan, Europe) |
- US FDA-approved manufacturing facilities: Global quality standards
- Cost-effective production: Affordable generic medications
- Extensive distribution networks: Global market reach
- Diverse formulation portfolios: Tablets, capsules, extended-release
| Company |
Drug |
Target |
Phase |
| Prothena |
Prasinezumab |
α-syn mAb |
Phase 2 |
| Biogen |
- |
α-syn ASO |
Phase 1 |
| Roche |
- |
α-syn mAb |
Phase 1 |
| Vaxxinity |
- |
α-syn vaccine |
Preclinical |
| Company |
Drug |
Mechanism |
Phase |
| Denali/Biogen |
DNL151 (BIIB122) |
LRRK2 inhibitor |
Phase 2b |
| Denali |
DNL261 |
LRRK2 inhibitor |
Phase 1 |
| Vanqua Bio |
VQVN000 |
LRRK2 inhibitor |
Preclinical |
| Gene |
Company |
Approach |
| GBA |
INmune Bio |
Enzyme modulation |
| LRRK2 |
Denali, Vanqua |
Small molecule inhibitors |
| GBA |
Gene therapy approaches |
Prevail, Passage Bio |
| Company |
Drug |
Mechanism |
Phase |
| Annovis Bio |
Bunodimod |
Sigma-1/mTOR |
Phase 2/3 |
| AbbVie |
- |
- |
Phase 2 |
| Company |
Approach |
Target |
| Prevail Therapeutics (Eli Lilly) |
AAV-GBA1 |
GBA mutation |
| Passage Bio |
AAV-GBA1 |
GBA mutation |
| Meiragtx |
- |
- |
| Phase |
Number of PD Trials |
| Phase 1 |
~40 |
| Phase 2 |
~80 |
| Phase 3 |
~30 |
- Genetic stratification: Trials increasingly target specific genetic subtypes (LRRK2, GBA)
- Biomarker development: Alpha-synuclein RT-QuIC, fluid biomarkers
- Early intervention: Targeting prodromal and early PD
- Combination approaches: Symptomatic + disease-modifying
Israel has a growing biotech ecosystem with several companies focused on Parkinson's disease and neurodegeneration:
| Company |
Key Drug/Program |
Mechanism |
Status |
| Pharma Two B |
P2B001 |
Dopamine agonist + COMT inhibitor |
Phase 3 |
| BrainStorm Cell Therapeutics |
NurOwn |
Cell therapy (MSC-NTF) |
Phase 1/2 |
| Mapi Pharma |
GA-GLP-1 |
GLP-1 receptor agonist |
Preclinical |
- Pharma Two B: Developing fixed-dose combination therapies for enhanced PD treatment
- BrainStorm Cell Therapeutics: Autologous cell therapy secreting neurotrophic factors
- Mapi Pharma: Enhanced formulation platform for CNS drugs
Digital therapeutics (DTx) for Parkinson's disease include prescription digital therapeutics, software-based interventions, and wearable-enabled rehabilitation platforms.
| Company |
Product/Focus |
Application |
Status |
| Kaia Health |
Kaia PD App |
Exercise, symptom tracking |
FDA registered |
| MedRhythms |
MR-001 |
Rhythmic auditory stimulation for gait |
FDA breakthrough |
| Rune Labs |
StrivePD |
Symptom tracking, wearable integration |
Available |
| LSVT Global |
LSVT BIG/LOUD |
Speech and movement therapy |
Clinical |
| PD Warrior |
Exercise programs |
Motor rehabilitation |
Published studies |
| Pear Therapeutics |
Platform |
Medication adherence, behavioral |
FDA-cleared (other) |
| Hinge Health |
MSK platform |
Exercise, fall prevention |
Clinical studies |
| Akili Interactive |
Cognitive platform |
Cognitive training |
FDA-approved (ADHD) |
MedRhythms (MR-001): Uses rhythmic auditory stimulation to improve gait in PD patients. FDA breakthrough device designation.
Kaia Health: Digital exercise platform with AI-powered motion tracking, FDA-registered medical device for PD.
Rune Labs (StrivePD): Apple Watch integration for continuous PD symptom monitoring and tracking.